Altogether, these results disclosed for the first time that the anti-tumor activity of regorafenib as a second-line drug for advanced HCC also relies on the FOXO3-induced cytoprotective autophagy inhibition, thereby supporting the involvement of this pro-survival mechanism in the sorafenib resistance acquisition. The gene discussed is FOXO3; the disease is neoplasm.